<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711503</url>
  </required_header>
  <id_info>
    <org_study_id>2007-007146-34</org_study_id>
    <secondary_id>EudraCT 2007-007146-34</secondary_id>
    <secondary_id>Danish EthicalH-D-2008-060</secondary_id>
    <secondary_id>Danish Datatilsyn2007-41-1652</secondary_id>
    <secondary_id>JDRF file no. 17-2007-1804</secondary_id>
    <nct_id>NCT00711503</nct_id>
  </id_info>
  <brief_title>Anti-Interleukin-1 in Diabetes Action</brief_title>
  <acronym>AIDA</acronym>
  <official_title>A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oeresund Diabetes Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the
      insulin production in patients with new onset Type 1 diabetes.

      Kineret® is already being used in the treatment of patients suffering from rheumatoid
      arthritis and preclinical studies are now suggesting that it may also be useful for patients
      with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a
      blocker of an immune-signal molecule named interleukin-1.

      The trial is a blinded randomised trial, in which the patient is allocated to receive the
      active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as
      add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the
      feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining
      or enhancing beta-cell function in people with new onset Type 1 diabetes.

      Trial Design:

      A randomized, placebo controlled, double masked, parallel group, multicentre trial of IL-1
      antagonism in subjects with newly-diagnosed Type 1 diabetes. Patients are instructed to
      inject 100 mg human recombinant interleukin-1 receptor antagonist (anakinra, Kineret®, Amgen,
      CA) or placebo s.c. once daily for 2 years. Endpoints will be evaluated every three months,
      with an interim analysis after 6 months.

      Trial population:

      The design will be a two-stage phase 2a study to address feasibility, safety/tolerability and
      potential efficacy. In the first phase 80 patients between 18 and 35 years of age with new
      on-set Type 1 diabetes will be randomized to anakinra or placebo, and endpoints will be
      analyzed as an interim analysis after 6 months by an independent data and safety monitoring
      board (DSMB). A futility analysis will be performed at this time point to prevent
      continuation of the trial if it shows no likelihood of demonstrating efficacy. In the event
      the trial does show promise of efficacy considering the power of the first phase based on a
      conditional analysis the DSMB can recommend prolongation of the study with recruitment to
      ensure adequate power, and that additional funding is provided.

      Methods and interventions:

      The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human
      non-glycosylated interleukin-1 receptor antagonist (anakinra) at a dose of 100 mg once daily
      or placebo by subcutaneous injection at the same time-point in the morning. Primary and
      secondary endpoints and safety parameters are investigated after 1 month and then every 3
      months.

      Safety:

      Anakinra is FDA approved for the indication rheumatoid arthritis and has an acceptable risk /
      benefit profile in this indication, with more than 100.000 patients treated. Most common
      ad-verse events include mild and transient local injection reactions in 20-50% of subjects
      treated with Anakinra. Consistent with its mechanism of action, anakinra reduces WBC/ANC in
      2.4% of patients and this may increase the risk of infection. Accordingly, treatment with
      anakinra will not be initiated in patients with active infections. Safety will be monitored
      by physical exams and blood and urine tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Δ 2-h AUC C-peptide response</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c &lt;7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients are instructed to administer placebo by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra</intervention_name>
    <description>The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>The patients are instructed to administer placebo (saline) once daily by subcutaneous injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes diagnosed according to WHO 1999 criteria

          -  Positive GAD auto-antibodies

          -  Age 18-35 yrs at onset of diabetes

          -  Time from first symptoms of diabetes &lt; 12 weeks

          -  Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test
             (Boost) at a test carried out when the subject is metabolically stable, i.e. after
             resolution of any polyuria, polydypsia or ketoacidosis.

        Exclusion Criteria:

          -  Severe liver or renal disease (creatinine &gt; 100 μmol/L, ASAT/ALAT &gt; 2* ULN, alkaline
             phosphatase &gt; 2 * ULN)

          -  History of heart disease, signs of cardiac failure or abnormal ECG

          -  Present or previous malignancy

          -  Pregnancy or failure of fertile female to comply with contraceptional planning, or
             breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and
             gestagen implants) . Plans of pregnancy within 2 years.

          -  Participation in other clinical intervention studies

          -  Anti-inflammatory therapy (except aspirin £ 100 mg/d)

          -  Active infections (CRP&gt;30), history of recurrent infection or predisposition to
             infections

          -  Neutropenia: ANC &lt; 1.5*109/L, or anaemia: Haemoglobin &lt; 8.0 g/dL

          -  Immune-suppressive treatment or immune-deficiency

          -  Presence at diagnosis of late diabetic complications

          -  Concurrent vaccination with live vaccine. Known need for live vaccinations within 2
             years.

          -  Use of Etanercept within 6 months before screening or during the double-blinded study
             period

          -  Hypersensitivity to E. coli-derived proteins, anakinra or any components of the
             product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Mandrup-Poulsen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Donath</last_name>
    <role>Study Director</role>
    <affiliation>Universtity of Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flemming Pociot, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Dinarello</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin Gale, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Bristol University, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Universitetshospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400 NV</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital, Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University, Dept. of Internal Medicine</name>
      <address>
        <city>Ulm</city>
        <state>Donau</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leibniz Center for Diabetes research, Heinrich-Heine University</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Diabetesforschung, Munich University of Technology</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15-269</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces, Diabetes Research Group</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnua de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Slovenia</country>
    <country>Sweden</country>
  </removed_countries>
  <reference>
    <citation>Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale. Diabetes Metab Res Rev. 2009 May;25(4):321-4. doi: 10.1002/dmrr.960. Review. Erratum in: Diabetes Metab Res Rev. 2009 Nov;25(8):780.</citation>
    <PMID>19405081</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Lise Tarnow</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>endogenous insulin production</keyword>
  <keyword>C-peptide level</keyword>
  <keyword>insulin requirement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

